Siti Nuraihan
Research Subjects
Siti Nuraihan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kin Fon Leong
Pediatric Institute, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia
2 shared publications - Adawiyah Jamil
Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Medicine, Kuala Lumpur, Malaysia.
1 shared publication - Agnes Yoke Hui Heng1 shared publication
- Azura Mohd Affandi
Department of Dermatology Hospital Kuala Lumpur Kuala Lumpur Malaysia
1 shared publication Emily Yiping Gan
Department of Dermatology, KK Women's and Children's Hospital, Singapore
1 shared publication- Evelyn Wen Yee Yap
Department of Dermatology Hospital Pakar Sultanah Fatimah Malaysia
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e89583
Current Management and Unmet Needs in Alopecia Areata: Viewpoint From a Malaysian Perspective
Alopecia areata (AA) is a chronic, immune-mediated disease characterized by nonscarring hair loss and a substantial clinical and psychosocial burden, yet it is still widely perceived as a purely cosmetic concern. In this viewpoint, we draw on the available Malaysian studies, selected international evidence, and our collective clinical experience to propose that AA warrants greater clinical, research, and policy attention in Malaysia. Malaysia-specific evidence remains limited and is derived largely from retrospective, single-center studies; nonetheless, the available data point to variable disease presentation, inconsistent use of standardized severity assessment, reliance on conventional therapies, substantial loss to follow-up, and a meaningful psychosocial impact among affected patients. Current local management appears to rely mainly on conventional therapies, while access to advanced therapies such as Janus kinase inhibitors remains constrained by affordability and reimbursement challenges. We therefore call for 5 priorities: strengthening Malaysia-specific epidemiological and real-world evidence, including through a national AA registry; adopting standardized disease-assessment tools in clinical studies and routine practice; integrating psychosocial support into AA care pathways; developing locally relevant clinical guidance; and improving public, clinician, and policymaker awareness that AA is a medical condition rather than a cosmetic concern. Together, these steps would support earlier diagnosis, more equitable access to effective treatment, and holistic, patient-centered care for adults and children living with AA in Malaysia.
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e89583
Open AccessCurrent Management and Unmet Needs in Alopecia Areata: Viewpoint From a Malaysian Perspective
Alopecia areata (AA) is a chronic, immune-mediated disease characterized by nonscarring hair loss and a substantial clinical and psychosocial burden, yet it is still widely perceived as a purely cosmetic concern. In this viewpoint, we draw on the available Malaysian studies, selected international evidence, and our collective clinical experience to propose that AA warrants greater clinical, research, and policy attention in Malaysia. Malaysia-specific evidence remains limited and is derived largely from retrospective, single-center studies; nonetheless, the available data point to variable disease presentation, inconsistent use of standardized severity assessment, reliance on conventional therapies, substantial loss to follow-up, and a meaningful psychosocial impact among affected patients. Current local management appears to rely mainly on conventional therapies, while access to advanced therapies such as Janus kinase inhibitors remains constrained by affordability and reimbursement challenges. We therefore call for 5 priorities: strengthening Malaysia-specific epidemiological and real-world evidence, including through a national AA registry; adopting standardized disease-assessment tools in clinical studies and routine practice; integrating psychosocial support into AA care pathways; developing locally relevant clinical guidance; and improving public, clinician, and policymaker awareness that AA is a medical condition rather than a cosmetic concern. Together, these steps would support earlier diagnosis, more equitable access to effective treatment, and holistic, patient-centered care for adults and children living with AA in Malaysia.
- Open Access
- 1 July 2023
- Published by Medknow in Indian Journal of Paediatric Dermatology
- Vol. 24 (3) , 232-235
Dupilumab as a Combination Therapy to Oral Systemic Immunomodulators for Moderate-to-Severe Atopic Dermatitis for Skin of Color Children in Resource-Limited Setting: A Case Series
Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.
- 1 July 2023
- Published by Medknow in Indian Journal of Paediatric Dermatology
- Vol. 24 (3) , 232-235
Open AccessDupilumab as a Combination Therapy to Oral Systemic Immunomodulators for Moderate-to-Severe Atopic Dermatitis for Skin of Color Children in Resource-Limited Setting: A Case Series
Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.
- 23 January 2023
- Published by Elsevier in The Journal of Pediatrics
- Vol. 257, 113331
Hypopigmented Macules in 3 Siblings
- 23 January 2023
- Published by Elsevier in The Journal of Pediatrics
- Vol. 257, 113331
Hypopigmented Macules in 3 Siblings
- Open Access
- 30 September 2022
- Published by Medknow in Indian Journal of Paediatric Dermatology
- Vol. 23 (4) , 325-327
Clouston Syndrome: A Complete Genotype–Phenotype Correlation after Four Decades and Six Generations
- 30 September 2022
- Published by Medknow in Indian Journal of Paediatric Dermatology
- Vol. 23 (4) , 325-327
Open AccessClouston Syndrome: A Complete Genotype–Phenotype Correlation after Four Decades and Six Generations